STOCK TITAN

Zymeworks (NASDAQ: ZYME) awards options, RSUs and PSUs to officer

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Zymeworks Inc. reported that officer Adam Schayowitz received new equity awards as part of his compensation. On April 9, 2026, he was granted stock options for 70,000 shares of common stock at an exercise price of $27.35 per share, expiring on April 8, 2036. These options vest 25% on the first anniversary of the grant and the rest in 36 monthly installments.

He also received 47,000 restricted stock units that vest in four equal annual installments, plus up to 76,000 performance stock units. The performance units can be earned between 50% and 200% of a 38,000-unit target based on cumulative total shareholder return over a three-year period ending on January 12, 2029, subject to continued service and specific TSR goals.

Positive

  • None.

Negative

  • None.
Insider Schayowitz Adam
Role See Remarks
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 70,000 $0.00 --
Grant/Award Restricted Stock Unit 47,000 $0.00 --
Grant/Award Performance Stock Unit 76,000 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct); Restricted Stock Unit — 47,000 shares (Direct); Performance Stock Unit — 76,000 shares (Direct)
Footnotes (1)
  1. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. RSUs vest in four equal annual installments beginning on first anniversary of grant date. Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index. (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Stock options granted 70,000 options Grant on April 9, 2026 at $27.35 exercise price
Option exercise price $27.35 per share Stock option grant to officer
Option expiration April 8, 2036 End date for 70,000 stock options
Restricted stock units 47,000 RSUs Grant vesting in four equal annual installments
Maximum performance stock units 76,000 PSUs Maximum earnable based on TSR over three-year period
PSU target amount 38,000 PSUs Target number with 50%-200% payout range
Restricted Stock Unit financial
"Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting..."
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
Performance Stock Unit financial
"Each performance restricted stock unit ("PSU") represents a contingent right to receive one share..."
A performance stock unit is a type of reward companies give to employees, usually managers, that depends on how well the company performs over time. If the company hits specific goals, the employee earns shares of stock, like earning a prize for reaching certain levels in a game. It motivates employees to work hard because their rewards are tied to the company's success.
cumulative total shareholder return financial
"may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals..."
Nasdaq Biotech Index financial
"if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index."
A Nasdaq biotech index is a stock market benchmark that tracks the performance of biotech and pharmaceutical companies listed on the Nasdaq exchange. Think of it as a thermometer for the biotech sector: it gives investors a single number showing how the group is doing, helps compare a company or fund against the sector, and guides decisions about sector exposure, risk and diversification because biotech stocks often move together and can be more volatile than the broader market.
vesting financial
"Stock options vest as follows: (i) 25% ... and (ii) remainder ... in 36 equal monthly installments..."
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Schayowitz Adam

(Last)(First)(Middle)
C/O ZYMEWORKS INC.
108 PATRIOT DRIVE, SUITE A

(Street)
MIDDLETOWN DELAWARE 19709

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
See Remarks
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$27.3504/09/2026A70,000 (1)04/08/2036Common Stock70,000$0.0070,000D
Restricted Stock Unit(2)04/09/2026A47,000 (3) (3)Common Stock47,000$0.0047,000D
Performance Stock Unit(4)(5)04/09/2026A76,000 (4)(5) (4)(5)Common Stock76,000$0.0076,000D
Explanation of Responses:
1. Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
2. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
3. RSUs vest in four equal annual installments beginning on first anniversary of grant date.
4. Each performance restricted stock unit ("PSU") represents a contingent right to receive one share of common stock. The amount reported is the maximum number of PSUs that may be earned upon achievement of certain cumulative total shareholder return ("TSR") goals over a three-year performance period ending on January 12, 2029 (or in some cases at earlier times). Between 50% and 200% of the target number of 38,000 PSUs ("Target Number") may be earned upon achievement of such TSR goals. 50% of the Target Number may be earned upon achievement of relative TSR goals if the Company's TSR for the performance period equals or exceeds a prespecified percentile for the Nasdaq Biotech Index.
5. (Continued from footnote 1) The PSUs will only vest at the end of the three-year performance period if the Reporting Person's service to the Company continues through such time that the board of directors of the Company certifies the achievement of TSR goals, except in certain limited cases (such as if service to the Company is terminated by the Company without cause or in case of a change of control).
Remarks:
EVP, Head of Research & Development
/s/ Catherine Graham, Attorney-in-Fact04/10/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did ZYME officer Adam Schayowitz receive?

Adam Schayowitz received stock options, restricted stock units, and performance stock units. The awards include 70,000 options at $27.35, 47,000 RSUs, and up to 76,000 PSUs, all tied to service and, for PSUs, performance conditions.

What are the terms of the ZYME stock options granted to Adam Schayowitz?

The grant covers 70,000 options with a $27.35 exercise price, expiring April 8, 2036. Vesting is 25% on the first anniversary of the grant, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on continued service.

How do the ZYME restricted stock units for Adam Schayowitz vest?

The 47,000 restricted stock units vest in four equal annual installments starting on the first anniversary of the grant date. Each vested RSU converts into one share of Zymeworks common stock, provided the officer remains in service through each vesting date.

How are ZYME performance stock units earned by Adam Schayowitz?

The performance stock units are tied to cumulative total shareholder return over a three-year period ending January 12, 2029. Between 50% and 200% of the 38,000-unit target, up to 76,000 PSUs, may be earned if specific TSR goals and service conditions are met.

What performance benchmark is used for ZYME PSUs granted to Adam Schayowitz?

The PSUs use cumulative total shareholder return metrics, including relative TSR versus the Nasdaq Biotech Index. At least 50% of the 38,000-unit target may be earned if the company’s TSR meets or exceeds a preset percentile for the index over the performance period.

Did Adam Schayowitz buy or sell ZYME shares in the open market?

The filing reports compensation-related equity grants only, not open-market trades. All three transactions are coded as awards (Code A), reflecting option, RSU, and PSU grants rather than purchases or sales on the public market.